以术后血细胞比容34%为目标的自动化红细胞置换在镰状细胞病慢性管理中的应用
该研究分析了101例接受慢性红细胞置换(RCE)且术后血细胞比容(Ht)目标为34%的镰状细胞病患者,其中多数为HbSS/HbSβ0基因型(n=72),53例因神经系统并发症入组。50例患者RCE后Ht呈正平衡,43例维持中性平衡;正平衡组每年所需红细胞单位更少(65 vs 80,p<0.001),但铁过载比例更高(基于肝脏MRI R2*为32% vs 未进行),铁螯合处方率更高(52% vs 0%,p<0.001)。结论认为术后Ht目标34%的慢性自动化RCE并非铁中性,个体化Ht目标可能更合适。
要点
- 慢性RCE术后Ht目标34%时,50例呈正平衡,43例呈中性平衡。
- 正平衡组每年红细胞需求更少(65 vs 80单位,p<0.001),但铁过载和铁螯合更常见。
- 中性平衡组更可能接受铁补充(6% vs 56%,p<0.001)。
核心结论
- 术后Ht目标34%的慢性自动化RCE并非铁中性,个体化Ht目标在某些情况下可能更合适。
- 该较高目标应与较低Ht策略在基线红细胞容量相似的人群中比较,以评估铁稳态和血液制品需求。
研究设计与样本
- 研究分析了101例接受慢性红细胞置换(RCE)且术后血细胞比容(Ht)目标为34%的镰状细胞病患者。
- 多数患者为HbSS/HbSβ0基因型(n=72),53例因神经系统并发症入组。
主要发现
- 50例患者RCE后Ht呈正平衡(较术前平均升高>2%),43例维持中性平衡。
- 正平衡组每年所需红细胞单位更少(65 vs 80,p<0.001)。
- 正平衡组基于肝脏MRI R2*的铁过载比例为32%,中性平衡组未进行检测。
- 正平衡组铁螯合处方率为52%,中性平衡组为0%(p<0.001,中位19个月后)。
- 中性平衡组接受铁补充的比例为56%,正平衡组为6%(p<0.001)。
关键数值与推荐
- 术后Ht目标为34%,高于通常使用的目标。
- Ht正平衡定义为RCE后较术前平均升高>2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Optimal targets for red blood cell exchange (RCE) are not well defined in the chronic management of sickle cell disease. We analysed transfusion requirements and iron-related outcomes in 101 patients on chronic RCE with a post-procedure haematocrit (Ht) targeted at 34%, which is higher than typically used. A majority were of HbSS/HbSβ0 genotype (n = 72) and enrolled for neurological complications (n = 53). Fifty patients had a positive Ht balance with RCE (>2% mean increase from pre-procedure level), while 43 patients maintained a neutral balance. The first group required fewer red blood cell units/year (65 vs. 80, p < 0.001), but a significant proportion were iron overloaded based on R2* with liver MRI (32% vs. none performed) and prescription of iron chelation (52% vs. 0%, p < 0.001, after a median of 19 months). The second group was more likely to receive iron supplementation (6% vs. 56%, p < 0.001). Chronic automated RCE with a post-procedure Ht targeted at 34% is not iron-neutral, and personalized Ht goals may be more appropriate in certain settings. This higher target should be compared with a lower Ht strategy in individuals with similar baseline red cell volumes to assess iron homeostasis and blood product requirements.
引用
- M Ross J, Forté S, Mercure-Corriveau N, et al. Automated red blood cell exchange with a post-procedure haematocrit targeted at 34% in the chronic management of sickle cell disease. Br J Haematol. 2024. PMID: 39081092. doi:10.1111/bjh.19674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。